Sirs: Polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS) is an incapacitating disorder that often runs a progressive course [7] . Evidence that MGUS autoantibody activity causes peripheral neuropathy has provided a rational basis for therapeutic intervention directed at lowering the monoclonal (M) protein concentration [4] . The optimal treatment regimen in terms of benefit and side effects is unknown. Although chemotherapy, with or without plasmapheresis, seems to be effective in some patients, it has potentially serious side effects [3, 6, 8, 9] . Treatment with pulsed high-dose dexamethasone is usually well tolerated [1, 2] . Based on the efficacy of dexamethasone as monotherapy in patients with multiple myeloma [1] and therapeutic resistant idiopathic trombocytopenic purpura [2] , we treated patients with a progressive polyneuropathy associated with MGUS with pulsed high-dose dexamethasone (40 mg per day orally for 4 consecutive days once a month in 6 cycles).
From 1993-1995, six patients with a progressive polyneuropathy associated with MGUS were treated with dexamethasone. None of the patients had previously been treated with immunosuppressive or cyctostatic therapy. The mean follow-up was 19 months (SD 5 months). Five patients had IgM-MGUS, all with antimyelin associated glycoprotein (MAG) antibodies, and one had only IgG-MGUS. Bone marrow biopsy showed no more than 10% plasma cells or more than 30% lymphoid cells, and no amyloid deposition (Congo red staining). Malignant plasma cell dyscrasias were excluded and no other cause of neuropathy was found.
The mean age at onset of the neuropathy was 59 years (SD 8). In all patients the sensory features of the neuropathy were more pronounced than the motor abnormalities. Electrophysiological studies showed a demyelinating neuropathy in two patients, axonal degeneration in one (IgG patient) and both demyelinating and axonal in three patients. Sural nerve biopsies were performed in four patients. Two patients had findings consistent with demyelination and two with demyelination and axonal degeneration. In three patients deposition of IgM was demonstrated. Mononuclear cell infiltrates were not present and Congo red staining was negative.
Treatment with dexamethasone was started because of progression of the neuropathy. After treatment two patients showed improved symptoms and signs (improvement = improvement of 1 or more points on the Rankin scale), with the onset of improvement 3 and 6 months after beginning treatment respectively ( Table  1) . The changes noted were a reduction in numbness, paraesthesia and improvement in strength [motor sumscore -summation of test results of six muscles of each arm and six Motor sumscore summation of test results of 6 muscles of each arm and 6 muscles of each leg using the MRC grading system (maximum score 120) b ΣCMAP summation of the compound muscle action potentials of median and peroneal nerve c ΣSNAP summation of the sensory nerve action potentials of median and sural nerve muscles of each leg using the MRC grading system (maximum score 120)]. Follow-up of these two patients has now been longer than 20 months. In three patients the neuropathy stabilized for more than 12 months of follow-up (stabilization = no change on the Rankin scale). Patient 6 further deteriorated and became wheelchair-bound despite treatment with dexamethasone (deterioration = deterioration of 1 or more points on the Rankin scale). After a period of 3 months without therapy, he received cyclophosphamide 500 mg for 4 days combined with prednisone 60 mg for 5 days at 4-week intervals for 6 months. After 6 months of cyclophosphamide therapy, the ataxia diminished and strength increased, so that he could walk again. The M-protein decreased to 2 g/l.
Four patients had serious side effects using WHO criteria (Table 1 ) [2] . Three patients suffered from severe mood disturbances during dexamethasone treatment and experienced the therapy as a rough remedy, greatly influencing their daily lives. One patient (4) wanted to stop after four cycles owing to these side effects and refused further treatment. Because of the observed side effects, enrolment was stopped after 6 patients.
We studied whether pulsed highdose dexamethasone treatment was effective in patients with a progressive polyneuropathy associated with MGUS, as we anticipated a potential immunosuppressive effect, by elimination of malignant plasma cells and/ or reduction of aberrant immunoglobulin production [1, 2] . In contrast to the mild side effects reported in the literature on pulsed high-dose dexamethasone treatment, we encountered a very high frequency of serious invalidating side effects [1, 2] . This is in contrast with high-dose dexamethasone treatment in patients with chronic inflammatory demyelinating polyneuropathy. Of ten patients, only one had serious side effects [5] . In this group of ten patients six had a clear beneficial response to treatment [5] . Possibly patients with polyneuropathy associated with MGUS are more susceptible to the toxic effects of high-dose dexamethasone. Therefore, although treatment with pulsed high-dose dexamethasone may prevent worsening of the neuropathy, we cannot recommend pulsed high-dose dexamethasone treatment as the first choice for patients with polyneuropathy associated with MGUS.
